IL2 and neoplasm: We determined the extent of pulmonary edema, a frequent toxicity of clinically dosed IL-2,7 induced by treatment with Y33 IC compared with IL-2/JES6 and Control IC for 3 consecutive days at 2 μg IL-2/dose, a schedule that was found to be therapeutic in our tumor models (online supplemental figure 13A).